Arbutus Biopharma Corporation
4.6100+0.03 (+0.66%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · ABUS · USD
Key Stats
Market Cap
883.73MP/E (TTM)
-Basic EPS (TTM)
-0.29Dividend Yield
0%Recent Filings
8-K
Arbutus HBV data posters accepted
Arbutus Biopharma announced four abstracts accepted for poster presentations at AASLD The Liver Meeting 2025, set for November 7–11 in Washington, DC, spotlighting imdusiran and AB-101 data in chronic hepatitis B trials. Three imdusiran posters detail safety across doses, enhanced genotype responsiveness to interferon, and immune biomarker boosts linked to HBsAg loss, while the AB-101 abstract, a Poster of Distinction, reports good tolerability and 83% PD-L1 receptor occupancy at 30 mg. This bolsters progress toward functional cures. Trials carry risks of delays or unfavorable outcomes.
8-K
Favorable patent ruling vs. Pfizer
Arbutus Biopharma and Genevant Sciences secured a favorable claim construction ruling on September 9, 2025, in their New Jersey patent infringement suit against Pfizer and BioNTech over lipid nanoparticle technology used in Comirnaty COVID-19 vaccines. The court defined key terms like 'lipid vesicle' broadly to encompass delivery compositions including liposomes, 'fully encapsulated' as 'contained inside,' and mol % ranges with standard rounding variations, while 'consisting essentially of' limits additives affecting nucleic acid activity, tolerability, or circulation stability. This bolsters Arbutus's infringement case, potentially unlocking damages from unauthorized use. Litigation drags on.
8-K
Q2 profit, rights reclaimed, board shift
Arbutus Biopharma reported Q2 2025 net income of $2.5 million, swinging from a $19.8 million loss last year, fueled by $10.7 million in revenue from reclaiming global rights to imdusiran after ending its Qilu partnership. Cash reserves stand at $98.1 million, down from $122.6 million at year-end, while R&D expenses dropped 65% to $5.5 million amid streamlining. Board shakeup: Anuj Hasija resigned August 4 for a Vertex role; Dr. Roger Sawhney joined with biotech expertise. Litigation against Moderna advances to trial in March 2026; Pfizer ruling pending. Patent fights drag on.
10-Q
Q2 FY2025 results
Arbutus Biopharma swung to a $2.5M net profit in Q2 FY2025 ended June 30, 2025, fueled by $10.7M revenue that rocketed 523% y/y from $1.7M, thanks to recognizing $9.6M deferred from the terminated Qilu partnership, while Q1's $24.5M loss stemmed from $12.4M restructuring charges after slashing workforce 57% and exiting in-house research. Operating expenses plunged 60% y/y to $9.3M, lifting the operating gain to $1.5M from a $21.6M loss. Cash and equivalents hit $37.4M, with total liquidity at $98.1M and no debt, supporting operations for at least 12 months; free cash flow not disclosed in the 10-Q. EPS reconciles at $0.01 diluted on 192M shares. Patent suits against Moderna and Pfizer/BioNTech drag on, with U.S. Moderna trial set for March 2026. Yet risks loom from clinical trial setbacks.
8-K
Arbutus reclaims imdusiran rights
Arbutus Biopharma terminated its 2021 license agreement with Qilu Pharmaceutical on June 20, 2025, reclaiming full rights to develop, manufacture, and commercialize imdusiran in Greater China and Taiwan amid Qilu's pipeline shifts and Arbutus' efficiency drive. No termination payments were involved, and Qilu must transfer all regulatory documents and data by June 30, 2025. The company also unveiled a new Scientific Advisory Board of HBV experts to guide late-stage trials. Rights revert cleanly, yet integration of transferred data poses execution risks.
ABVC
ABVC Biopharma, Inc.
2.77-0.13
ABVX
Abivax SA
98.94+4.70
ANAB
AnaptysBio, Inc.
36.12-0.04
ARMP
Armata Pharmaceuticals, Inc.
5.46+0.47
ASMB
Assembly Biosciences, Inc.
30.99+0.10
AVIR
Atea Pharmaceuticals, Inc.
3.29+0.08
CRBP
Corbus Pharmaceuticals Holdings
16.86-0.26
CUE
Cue Biopharma, Inc.
0.69-0.05
ENTA
Enanta Pharmaceuticals, Inc.
10.63+0.16
VIR
Vir Biotechnology, Inc.
5.91-0.52